Image Place holder

Rutika Mehta, MD, MPH


Specialty: Medical Oncology
Program: Gastrointestinal Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Cancer Types Treated: Colorectal Cancer , Esophageal Cancer , Gallbladder Cancer , Liver Cancer , Pancreatic Cancer , Small Intestine Cancer , Stomach (Gastric) Cancer , Anal Cancer, Colon Cancer

Dr. Mehta received her MD degree from Topiwala National Medical College, Mumbai, India. She received a Master of Science in Public Health in Epidemiology at St. Louis University School of Public Health at Indiana University, followed by a Master of Public Health in Epidemiology at Purdue University, Indianapolis Indiana. Dr. Mehta also completed a one-year Research Fellowship in Pathology at Indiana University School of Medicine, Translational Genomics Core. She completed her Internal Medicine Residency at Johns Hopkins University/Sinai Hospital of Baltimore, Maryland. Dr. Mehta recently completed a Hematology/Oncology Fellowship at the University of Buffalo, Roswell Park Cancer Institute, Buffalo, New York. Dr. Mehta’s clinical interests are a spectrum of gastrointestinal cancers including esophageal, gastric, hepato-biliary, pancreatic and colorectal cancers, both early stages and advanced stages. Dr. Mehta’s research interests are primarily esophageal/gastric cancers and colon cancer. She is interested in bringing basic research to the clinic by developing innovative clinical trials for patients.

Education & Training

Board Certification:

  • Internal Medicine

Fellowship:

  • University of Buffalo/Roswell Park Cancer Institute - Hematology Oncology

Residency:

  • Johns Hopkins University/Sinai Hospital of Baltimore - Internal Medicine

Medical School:

  • Topiwala National Medical College, Mumbai, India - MBBS
Participating Trials

CLINICAL TRIAL 17932
A Phase 1a/1b Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer
Condition:
Intervention: BAY 43-9006 (Sorafenib); GSK1120212 (Trametinib); Sorafenib; Trametinib
Open

CLINICAL TRIAL 18435
Phase II study of Copanlisib (BAY 80-6946) in Combination with Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
Condition:
Intervention: BAY 80-6946 (Copanlisib); Copanlisib; Gemzar (gemcitabine); cisplatin; gemcitabine
Open

CLINICAL TRIAL 18322
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma
Condition:
Intervention: BLU-554
Open

CLINICAL TRIAL 18837
An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Condition:
Intervention: Dexamethasone; Rovalpituzumab Tesirine
Open

CLINICAL TRIAL 18646
Phase I Study of Pre-operative Capecitabine and Lenvatinib with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma
Condition:
Intervention: E7080 (Lenvatinib); Lenvatinib (Lenvima); Xeloda (capecitabine); capecitabine
Open

CLINICAL TRIAL 18051
A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients with Relapsed/Refractory Metastatic Colorectal Carcinoma
Condition:
Intervention: MGD007
Open

CLINICAL TRIAL 19112
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Condition:
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19185
An Open Label, Single Arm Pilot Study of OncoSil, Administered to Subjects with Unresectable Locally Advanced Pancreatic Adenocarcinoma, Given in Combination with Gemcitabine or Gemcitabine+Nab-Paclitaxel Chemotherapies
Condition:
Intervention: Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); OncoSil Microparticles / Diluent; gemcitabine
Open

CLINICAL TRIAL 19302
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an anti-LAG-3 Monoclonal Antibody, alone and in combination with an anti-PD-1 in Patients with Advanced Solid Tumors
Condition:
Intervention: Not Applicable; TSR-033; TSR-042
Open

CLINICAL TRIAL 19091
A Phase I/II Study of Pembrolizumab in Combination with Ibrutinib for Advanced, Refractory Colorectal Cancers
Condition:
Intervention: 748645 (Ibrutinib); Ibrutinib (Imbruvica); PCI-32765 (Ibrutinib); Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18684
A Phase II Investigator Sponsored Study of Nivolumab in Patients with Advanced Refractory Biliary Tract Cancers
Condition:
Intervention: BMS-936558 (Nivolumab); Nivolumab
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition:
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-042
Open

CLINICAL TRIAL 19384
A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab (MK-3475) plus Binimetinib alone or the Combination of Pembrolizumab plus Chemotherapy with or without Binimetinib in Participants with Metastatic Colorectal Cancer (KEYNOTE-651)
Condition:
Intervention: Binimetinib; FOLFIRI; FOLFOX; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 19460
An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-164, an Antibody-Drug Conjugate, in Patients with Advanced Gastrointestinal Cancers Expressing Guanylyl Cyclase C
Condition:
Intervention: TAK-164
Open

CLINICAL TRIAL 19497
A Randomized, Crossover Phase 1 Study to Evaluate the Effects of Pevonedistat on the QTc Interval in Patients With Advanced Solid Tumors
Condition:
Intervention: MLN4924 (Pevonedistat); Paraplatin (carboplatin); Pevonedistat; Taxol (paclitaxel); Taxotere (docetaxel); carboplatin; docetaxel; paclitaxel
Open

CLINICAL TRIAL 19594
A Multicenter, Non-Randomized, Open-label Dose Escalation Phase Ib Study of Regorafenib in Combination with Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma (HCC) with No Prior Systemic Therapy.
Condition:
Intervention:
Open

CLINICAL TRIAL 19483
A Phase III, Open-Label, Randomized Study Of Atezolizumab In Combination With Bevacizumab Compared With Sorafenib In Patients With Untreated Locally Advanced Or Metastatic Hepatocellular Carcinoma
Condition:
Intervention: Atezolizumab (Tecentriq); Avastin (Bevacizumab); BAY 43-9006 (Sorafenib); Bevacizumab; Sorafenib
Open

CLINICAL TRIAL 19615
A Phase 1b/2, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 x CD3 DART Protein in Combination with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Metastatic Colorectal Carcinoma
Condition:
Intervention: MGA012; MGD007
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Jasra S, Opyrchal M, Norton L, Mehta R. A Rare Case of S310F Somatic ERBB2 Mutation in a HER2-Nonamplified Breast Cancer. Clin Breast Cancer. 2017 Feb;17(1):e37-e41. Pubmedid: 27665021.
  • Miller K, Mehta R, Abraham J, Opneja A, Jain RK. Patterns of Long-term Cancer Survivorship Care in a National Cancer Institute-Designated Comprehensive Cancer Center. Am J Clin Oncol. 2017 Dec;40(6):639-643. Pubmedid: 26359697.
  • Miller KD, Pandey M, Jain R, Mehta R. Cancer Survivorship and Models of Survivorship Care: A Review. Am J Clin Oncol. 2015 Dec;38(6):627-633. Pubmedid: 25635609.
  • Gökmen-Polar Y, Goswami CP, Toroni RA, Sanders KL, Mehta R, Sirimalle U, Tanasa B, Shen C, Li L, Ivan M, Badve S, Sledge GW. Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer. J Cancer. 2014 Aug;5(8):633-645. Pubmedid: 25157274. Pmcid: PMC4142325.
  • Vladislav T, Jain RK, Alvarez R, Mehta RJ, Gökmen-Polar Y, Kesler KA, Henley JD, Loehrer PJ, Badve S. Extrathoracic metastases of thymic origin: a review of 35 cases. Mod Pathol. 2012 Mar;25(3):370-377. Pubmedid: 22080058.
  • Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H, Badve S. FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat. 2012 Feb;131(3):881-890. Pubmedid: 21503684.
  • Gökmen-Polar Y, Liu Y, Toroni RA, Sanders KL, Mehta R, Badve S, Rommel C, Sledge GW. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. Breast Cancer Res Treat. 2012 Dec;136(3):673-682. Pubmedid: 23085766.
  • Mehta R, Jain RK, Badve S. Personalized medicine: the road ahead. Clin Breast Cancer. 2011 Mar;11(1):20-26. Pubmedid: 21421518.
  • Patel JB, Appaiah HN, Burnett RM, Bhat-Nakshatri P, Wang G, Mehta R, Badve S, Thomson MJ, Hammond S, Steeg P, Liu Y, Nakshatri H. Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene. 2011 Mar;30(11):1290-1301. Pubmedid: 21057539.
  • Jain RK, Mehta R, Dimitrov R, Larsson LG, Musto PM, Hodges KB, Ulbright TM, Hattab EM, Agaram N, Idrees MT, Badve S. Atypical ductal hyperplasia: interobserver and intraobserver variability. Mod Pathol. 2011 Jul;24(7):917-923. Pubmedid: 21532546.
  • Johnson EO, Chang KH, de Pablo Y, Ghosh S, Mehta R, Badve S, Shah K. PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer. J Cell Sci. 2011 Aug;124(Pt 16):2711-2722. Pubmedid: 21807936.
  • Jain RK, Mehta RJ, Nakshatri H, Idrees MT, Badve SS. High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology. 2011 Apr;58(5):766-772. Pubmedid: 21401706.
  • Appaiah H, Bhat-Nakshatri P, Mehta R, Thorat M, Badve S, Nakshatri H. ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer. Cancer Biol Ther. 2010 Sep;10(6):600-614. Pubmedid: 20603605. Pmcid: PMC3040950.
  • McCune K, Mehta R, Thorat MA, Badve S, Nakshatri H. Loss of ERα and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model. Oncol Rep. 2010 Nov;24(5):1233-1239. Pubmedid: 20878115. Pmcid: PMC2948410.
  • Gökmen-Polar Y, Mehta R, Tuzmen S, Mousses S, Thorat MA, Sanders KL, Turbin D, Leung S, Huntsman DG, Sledge GW, Badve S. Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes. Breast Cancer Res Treat. 2010 Nov;124(2):327-335. Pubmedid: 20099025.
  • Geyer FC, Lambros MB, Natrajan R, Mehta R, Mackay A, Savage K, Parry S, Ashworth A, Badve S, Reis-Filho JS. Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. Mod Pathol. 2010 Jul;23(7):951-960. Pubmedid: 20453835.
  • Jain RK, Mehta RJ, Henley JD, Kesler KA, Loehrer PJ, Badve S. WHO types A and AB thymomas: not always benign. Mod Pathol. 2010 Dec;23(12):1641-1649. Pubmedid: 20834239.
  • Jain RK, Mehta R, Badve S. Conjunctival squamous cell carcinoma due to ocular prostheses: a case report and review of literature. Pathol Oncol Res. 2010 Dec;16(4):609-612. Pubmedid: 20376710.
  • Mehta R, Jain RK, Sneige N, Badve S, Resetkova E. Expression of high-molecular-weight cytokeratin (34betaE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast. J Clin Pathol. 2010 Aug;63(8):744-747. Pubmedid: 20702478.
  • Resetkova E, Reis-Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H, Badve S. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat. 2010 Aug;123(1):97-108. Pubmedid: 19911270.